On 22 September 2026, the US CFTC issued a staff advisory on mention market contracts. The Division of Market Oversight (DMO) identified heightened manipulation risks associated with these event contracts. Their outcomes depend on individuals’ words, attendance or interactions. The advisory explains the limited circumstances in which listing may comply with existing law. It addresses contract design, trading controls and submissions by designated contract markets (DCMs).1
What Are Mention Market Contracts?
Mention markets allow participants to trade on whether an individual performs specified conduct. Examples include using particular phrases during speeches or earnings calls, attending events or interacting with others. The advisory also covers comparable risks involving small groups capable of jointly influencing an outcome. The concern arises where someone can control settlement or exploit advance knowledge of the outcome. A podcast host, for example, may control whether the relevant catchphrase is spoken. Access to scripts, prepared remarks, guest lists or unpublished content may also create informational advantages. Public visibility alone may provide insufficient protection. Staff notes that an unrelated buzzword during an earnings call could escape meaningful scrutiny. The significance of the words or conduct within their context therefore matters.2
Core Principle 3 and Manipulation Risk
Core Principle 3 appears in section 5(d)(3) of the United States Commodity Exchange Act. It requires DCMs to list only contracts that are not readily susceptible to manipulation. DMO staff states that it may view mention markets as “presumptively readily susceptible to manipulation”. Staff accordingly expects heightened support for submissions seeking to list these contracts. The assessment remains specific to each contract and its safeguards. In limited circumstances, appropriate design, trading rules, surveillance and controls may rebut that presumption. Listing must remain consistent with Core Principle 3.2
Four Factors for Assessing Mention Market Contracts
The advisory identifies four non-exhaustive factors relevant to the staff assessment:
| Factor | Assessment expected from DCMs |
|---|---|
| Independent obligations affecting the individual | Consider whether legal, professional, contractual, fiduciary or other duties meaningfully deter interference with settlement. Potential consequences should be assessed against the available financial gain. |
| Exposure to external pressure | Assess whether inducements, social engineering or pressure campaigns could influence the individual or their associates. |
| Independent verification and public scrutiny | Examine whether outcomes are independently verifiable and receive substantial scrutiny when they occur. Consider the substantive significance of the relevant words or actions. |
| Preventive trading rules, surveillance and controls | Demonstrate how measures address manipulation, attempted manipulation and misappropriation of non-public information. Controls should reflect the risks of the particular contract. |
The advisory strongly encourages DCMs to identify potential controllers and known insiders. Suggested measures include affiliation screening, restricted lists, appropriately calibrated position limits and targeted surveillance. Monitoring may examine unusual profit patterns, trading before announcements and account creation or funding times. Independent duties binding the relevant individual do not replace the DCM’s own preventive measures.3
Part 40 Submissions and Product Listing
Regulation 40.2 governs product listing by self-certification. Regulation 40.3 provides a voluntary route for Commission review and approval. Both require analysis demonstrating compliance with applicable statutory and regulatory requirements.4 For mention markets, DMO staff expects filings to evaluate each factor thoroughly. Submissions should explain the controls already implemented in sufficient detail to permit staff assessment. The advisory encourages engagement with DMO during product design and before filing.3 For DCMs developing these products, the practical focus is evidence supporting the individual contract’s design. Submissions should connect identified manipulation risks with the controls intended to address them.
Footnotes
- US CFTC, CFTC Releases Staff Advisory on Mention Markets, Release No. 9302-26, 22 September 2026.
- US CFTC, Division of Market Oversight, Staff Advisory on Individual Mention, Attendance and Interaction Event Contracts, CFTC Letter No. 26-27, 22 September 2026, pp. 1–3 and 5; Commodity Exchange Act, section 5(d)(3), 7 U.S.C. § 7(d)(3).
- US CFTC, CFTC Letter No. 26-27, pp. 4–6, including footnotes 14–15.
- 17 CFR § 40.2(a)(3)(v) and 17 CFR § 40.3(a)(4).
